The user experienced hair regrowth using a topical solution containing 5% minoxidil and 0.1% finasteride, despite an initial shedding phase. They reported no side effects and noted significant improvement in hair density, particularly around the crown area.
A user shared their 6.5-month experience with topical finasteride (2%) and minoxidil (5%), noting initial progress followed by a significant shedding phase. Others in the conversation reassured that shedding is normal and suggested staying consistent with the treatment for potential regrowth.
The user successfully managed hair loss using Finasteride, Minoxidil, Ketoconazole shampoo, and a hair mask, experiencing significant hairgrowth and improved density. They attribute their success to consistency, improved nutrition, and a dedicated routine.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
A user shared a beard growth protocol involving hydration toner, azelaic acid, tretinoin, moisturizer, 5% topical minoxidil, and SPF 30+ sunscreen. The regimen spans a year to a year and a half, with specific application schedules for different phases.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hairgrowth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
The conversation discusses using finasteride or dutasteride to reduce DHT, CosmeRNA to target androgen receptors, and Minoxidil as a vasodilator for hairgrowth. The regimen aims to maintain hair by addressing DHT-AR ratio and continuous Minoxidil use.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hairgrowth, could be alternative to Minoxidil and Finasteride.
The user's hair thinning and shedding were due to Telogen effluvium caused by COVID-19, not the ineffectiveness of Finasteride. The shedding eventually slowed, and hairgrowth resumed, but the user was advised to consider additional treatments like Minoxidil or microneedling if needed.
A 21-year-old shared their 6-month hair regrowth journey using daily finasteride tablets and once-daily topical minoxidil, noting significant improvement in hair thickness, especially at the corners, with minimal side effects. They also mentioned using minoxidil for beard growth with limited success and occasionally using a dermaroller.
A user shared their positive experience with a crown MicroFUE hair transplant at Boston Hair Restoration, highlighting the smooth procedure, minimal pain, and significant growth over 12 months. They used oral minoxidil, finasteride (transitioning to dutasteride), PRP sessions, and a LaserCap, achieving excellent results and full confidence.
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
Finasteride is more effective for long-term hair maintenance by addressing the root cause of hair loss, while minoxidil acts as a growth stimulant with faster visible results. Combining both treatments is optimal, with oral minoxidil often showing better results for some individuals.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hairgrowth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
Treating Black/ethnic hair loss with a combination of Minoxidil, finasteride, Nizoral shampoo and derma pen treatments, as well as occasional Jamaican Black Caster Oil use. The user documented their progress over the course of 3.5 months, showing improvement in hairgrowth.
The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.
A user's father, mostly bald for 20 years, is regrowing hair using a serum called "Skrzypovita Serum Pro" without minoxidil. The user is curious about which ingredients might be causing hairgrowth.
Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hairgrowth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.
The user started finasteride a month ago and experienced significant hair shedding, which is considered a sign that the treatment is working. Many users suggest combining finasteride with minoxidil and possibly shaving the head to manage the shedding phase.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
The user has been using minoxidil on their hairline for about six months and is also on finasteride. They are considering applying minoxidil to the rest of their scalp to improve hair density but are concerned about potential shedding.
The conversation is about someone using minoxidil, biotin, a laser cap, and a derma roller for hair loss, and considering finasteride. Some users are skeptical about the treatments, while others advise patience for results.
A 26-year-old male shared results after using Minoxidil twice daily and dermarolling weekly for two months, seeking advice on additional treatments for better hairgrowth. Another user discussed their experience with finasteride and considered trying dutasteride due to concerns about hair shedding and lack of regrowth.
Hairgrowth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
PP405 shows potential for hairgrowth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.
BPC-157 may promote hairgrowth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.
PP405 may induce new hairgrowth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.